Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Therapy
  4. Fast Track Articles
  5. Fast Track Article
image of Novel Pharmaceutical Interventions for Drug Targeting in Parkinson’s Disease

Abstract

Parkinson's Disease (PD) presents as a neurodegenerative disorder characterized by a gradual decline in brain function, typically advancing slowly over time in most individuals. However, as the disease evolves and impacts the Gastrointestinal Tract (GIT), the window for effective treatment response often becomes narrower for many patients. Recent advancements in medical science have spurred improvements in drug delivery, primarily through the development of enhanced oral formulations or the exploration of alternative administration routes, such as intestinal infusion, transcutaneous delivery, and inhaled levodopa. Among the recent oral formulation breakthroughs is IPX066, a novel formulation combining immediate and extended-release Carbidopa-Levodopa (CD/LD). Another notable example is levodopa-carbidopa intestinal gel, an authorized treatment involving the direct infusion of LD/CD suspension into the brain. Concurrent investigations are assessing the effectiveness of the 'accordion pill' (AP09004), an Extended-release (ER) LD/CD mixture designed to retain within the GIT for an extended period. Additionally, other formulations in various stages of clinical trials include ND0612, a proprietary liquid formulation intended for the purpose of subcutaneous delivery using a compact patch-pump apparatus, and CVT-301, a levodopa aerosol solution distinguished by its prompt initiation of therapeutic effects. However, several other promising formulations, such as DM-1992 and XP21279, have been terminated. This study aimed to thoroughly examine the pharmacokinetics, clinical effectiveness, and possible adverse reactions linked to innovative medication formulations that are now accessible or being developed for treating PD.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855311148240923100039
2024-10-17
2025-04-24

  • From This Site

    /content/journals/cdth/10.2174/0115748855311148240923100039
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. George J. Mok S. Moses D. Wilkins S. Bush A. Cherny R. Finkelstein D. Targeting the progression of Parkinson’s disease. Curr. Neuropharmacol. 2009 7 1 9 36 10.2174/157015909787602814 19721815
    [Google Scholar]
  2. Costa H.N. Esteves A.R. Empadinhas N. Cardoso S.M. Parkinson’s disease: A multisystem disorder. Neurosci. Bull. 2023 39 1 113 124 10.1007/s12264‑022‑00934‑6 35994167
    [Google Scholar]
  3. Hussain S. Khan M.A. Rajan R. Jyoti J. Sharma S. Sahu S.K. Nanorobots: The future of healthcare. Proceedings of the International Conference on Materials for Emerging Technologies Phagwara, Punjab 2023 10.1063/5.0162904.
    [Google Scholar]
  4. Hayes M.T. Parkinson’s disease and parkinsonism. Am. J. Med. 2019 132 7 802 807 10.1016/j.amjmed.2019.03.001 30890425
    [Google Scholar]
  5. Gutiérrez J. Singer C. Parkinsonism: alternative diagnosis beyond idiopathic Parkinson’s disease. Rev. Med. Inst. Mex. Seguro Soc. 2010 48 3 279 292 21192900
    [Google Scholar]
  6. Dézsi L. Vécsei L. Established therapies and novel targets in the treatment of Parkinson’s disease. Expert Rev. Clin. Pharmacol. 2009 2 6 631 644 10.1586/ecp.09.47 22112257
    [Google Scholar]
  7. Donzuso G. Cicero C.E. Vinciguerra E. Sergi R. Luca A. Mostile G. Terravecchia C. Zappia M. Nicoletti A. Gender differences in non-motor fluctuations in Parkinson’s disease. J. Neural Transm. (Vienna) 2023 130 10 1249 1257 10.1007/s00702‑023‑02679‑6 37526768
    [Google Scholar]
  8. Picillo M. Nicoletti A. Fetoni V. Garavaglia B. Barone P. Pellecchia M.T. The relevance of gender in Parkinson’s disease: A review. J. Neurol. 2017 264 8 1583 1607 10.1007/s00415‑016‑8384‑9 28054129
    [Google Scholar]
  9. Deleu D. Northway M.G. Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin. Pharmacokinet. 2002 41 4 261 309 10.2165/00003088‑200241040‑00003 11978145
    [Google Scholar]
  10. Freitas M.E. Ruiz-Lopez M. Fox S.H. Novel levodopa formulations for Parkinson’s disease. CNS Drugs 2016 30 11 1079 1095 10.1007/s40263‑016‑0386‑8 27743318
    [Google Scholar]
  11. Hussain M.S. Gupta G. Samuel V.P. Almalki W.H. Kazmi I. Alzarea S.I. Saleem S. Khan R. Altwaijry N. Patel S. Patel A. Singh S.K. Dua K. Immunopathology of herpes simplex virus‐associated neuroinflammation: Unveiling the mysteries. Rev. Med. Virol. 2024 34 1 e2491 10.1002/rmv.2491 37985599
    [Google Scholar]
  12. Dempski R.E. Scholtz E.C. Oberholtzer E.R. Yeh K.C. Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 1989 39 11 20 24 2685648
    [Google Scholar]
  13. Afroz F. Bach C. Improvement in drug delivery system for Parkinson’s disease. ASEE 2014 Zone I Conference University of Bridgeport, Bridgpeort, CT, USA 2014
    [Google Scholar]
  14. Hussain M.S. Altamimi A.S.A. Afzal M. Almalki W.H. Kazmi I. Alzarea S.I. Gupta G. Shahwan M. Kukreti N. Wong L.S. Kumarasamy V. Subramaniyan V. Kaempferol: Paving the path for advanced treatments in aging-related diseases. Exp. Gerontol. 2024 188 112389 10.1016/j.exger.2024.112389 38432575
    [Google Scholar]
  15. Gupta P.N. Mishra V. Rawat A. Dubey P. Mahor S. Jain S. Chatterji D.P. Vyas S.P. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: A comparative study. Int. J. Pharm. 2005 293 1-2 73 82 10.1016/j.ijpharm.2004.12.022 15778046
    [Google Scholar]
  16. Mizuno Y. Definition and classification of Parkinsonian drugs. NeuroPsychopharmacotherapy Riederer P. Laux G. Nagatsu T. Springer 2022 2823 2852 10.1007/978‑3‑030‑62059‑2_213.
    [Google Scholar]
  17. Tripathi K. Essentials of Medical Pharmacology Jaypee Brothers Medical Publishers New Delhi 2013 816 835
    [Google Scholar]
  18. Dave P.N. Macwan P.M. Advanced fiber materials in drug delivery. Fiber Materials: Design, Fabrication and Applications Wiley 2023 273 326 10.1515/9783110992892‑011
    [Google Scholar]
  19. Andrade I. Jr Sousa A.B.S. Silva G.G. New therapeutic modalities to modulate orthodontic tooth movement. Dental Press J. Orthod. 2014 19 6 123 133 10.1590/2176‑9451.19.6.123‑133.sar 25628089
    [Google Scholar]
  20. Padilla-Godínez F.J. Ruiz-Ortega L.I. Guerra-Crespo M. Nanomedicine in the face of Parkinson’s disease: from drug delivery systems to nanozymes. Cells 2022 11 21 3445 10.3390/cells11213445 36359841
    [Google Scholar]
  21. Liu X. Yuan M. Li L. Zhang J. Huang X. Du J. Tu Z. Wu H. Research progress of nanocarriers for the treatment of Alzheimer’s Disease. Curr. Pharm. Des. 2023 29 2 95 115 10.2174/1381612829666221216114912 36529920
    [Google Scholar]
  22. Alabrahim O.A.A. Azzazy H.M.E.S. Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson’s disease. Nanoscale Adv. 2022 4 24 5233 5244 10.1039/D2NA00524G 36540116
    [Google Scholar]
  23. Masood N. Jimenez-Shahed J. Effective management of “OFF” episodes in Parkinson’s disease: Emerging treatment strategies and unmet clinical needs. Neuropsychiatr. Dis. Treat. 2023 19 247 266 10.2147/NDT.S273121 36721795
    [Google Scholar]
  24. McKay J.L. Lang K.C. Ting L.H. Hackney M.E. Impaired set shifting is associated with previous falls in individuals with and without Parkinson’s disease. Gait Posture 2018 62 220 226 10.1016/j.gaitpost.2018.02.027 29571090
    [Google Scholar]
  25. Pahwa R. Lyons K.E. Outpatient titration of carbidopa/levodopa enteral suspension (Duopa). Int. J. Neurosci. 2017 127 5 459 465 10.1080/00207454.2016.1193862 27222011
    [Google Scholar]
  26. Virhammar J. Nyholm D. Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: Clinical evidence and experience. Ther. Adv. Neurol. Disord. 2017 10 3 171 187 10.1177/1756285616681280 28344656
    [Google Scholar]
  27. Tall P. Qamar M.A. Batzu L. Leta V. Falup-Pecurariu C. Ray Chaudhuri K. Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease. J. Neural Transm. (Vienna) 2023 130 11 1443 1449 10.1007/s00702‑023‑02640‑7 37126118
    [Google Scholar]
  28. Seeberger L.C. Hauser R.A. Carbidopa levodopa enteral suspension. Expert Opin. Pharmacother. 2015 16 18 2807 2817 10.1517/14656566.2015.1111336 26595228
    [Google Scholar]
  29. Lungare S. Bowen J. Badhan R. Development and evaluation of a novel intranasal spray for the delivery of amantadine. J. Pharm. Sci. 2016 105 3 1209 1220 10.1016/j.xphs.2015.12.016 26886345
    [Google Scholar]
  30. Khatri D.K. Preeti K. Tonape S. Bhattacharjee S. Patel M. Shah S. Singh P.K. Srivastava S. Gugulothu D. Vora L. Singh S.B. Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy. Curr. Neuropharmacol. 2023 21 3 493 516 10.2174/1570159X20666220507022701 35524671
    [Google Scholar]
  31. Agrawal M. Saraf S. Saraf S. Antimisiaris S.G. Chougule M.B. Shoyele S.A. Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J. Control. Release 2018 281 139 177 10.1016/j.jconrel.2018.05.011 29772289
    [Google Scholar]
  32. Caraco Y. Oren S. LeWitt P. Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/carbidopa (CD). In: Movement Disorders WILEY-BLACKWELL NJ USA 2013
    [Google Scholar]
  33. Richmond A.M. Lyons K.E. Pahwa R. Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease. Expert Opin. Drug Saf. 2023 22 7 563 579 10.1080/14740338.2023.2227096 37401865
    [Google Scholar]
  34. Giladi N. Caraco Y. Gurevitch T. Djaldetti R. Cohen Y. Yacobi-Zeevi O. Pharmacokinetics and safety of ND0612L (levodopa/carbidopa for subcutaneous infusion): Results from a phase II study in moderate to severe Parkinson’s disease. 2015 Available from: https://neuroderm.com/media/upbnn4sb/pk-safety.pdf
  35. Antonini A. Chaudhuri K.R. Martinez-Martin P. Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 2010 24 2 119 129 10.2165/11310940‑000000000‑00000 20088619
    [Google Scholar]
  36. Reichmann H. Poewe W. Ebersbach G. Müller T. New developments for Parkinson's therapy with COMT inhibitors. EMJ Neurol 2017 5 2 10 10.33590/emjneurol/10310764.
    [Google Scholar]
  37. Hengartner D. Fernandez H.H. The next chapter in symptomatic Parkinson disease treatments. Parkinsonism Relat. Disord. 2019 59 39 48 10.1016/j.parkreldis.2019.01.002 30661840
    [Google Scholar]
  38. Lipp M.M. Hickey A.J. Langer R. LeWitt P.A. A technology evaluation of CVT-301 (Inbrija): An inhalable therapy for treatment of Parkinson’s disease. Expert Opin. Drug Deliv. 2021 18 11 1559 1569 10.1080/17425247.2021.1960820 34311641
    [Google Scholar]
  39. Ray Chaudhuri K. Qamar M.A. Rajah T. Loehrer P. Sauerbier A. Odin P. Non-oral dopaminergic therapies for Parkinson’s disease: Current treatments and the future. npj. Parkinsons Dis. 2016 2 1 1 7
    [Google Scholar]
  40. Hauser RA. IPX066: A novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother 2012 12 2 133 40 10.1586/ern.11.195.
    [Google Scholar]
  41. Stocchi FHA. Khanna S. Ellenbogen A. Mahler A. Liang G. Dillmann U. Rubens R. Kell S. Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 2014 20 12 1335 40 10.1016/j.parkreldis.2014.08.004.
    [Google Scholar]
  42. Pilleri M. Antonini A. Novel levodopa formulations in the treatment of Parkinson’s disease. Expert Rev. Neurother. 2014 14 2 143 149 10.1586/14737175.2014.877840 24428803
    [Google Scholar]
  43. Pahwa R. Lyons K.E. Hauser R.A. Fahn S. Jankovic J. Pourcher E. Hsu A. O’Connell M. Kell S. Gupta S. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat. Disord. 2014 20 2 142 148 10.1016/j.parkreldis.2013.08.017 24055014
    [Google Scholar]
  44. Luinstra M. Grasmeijer F. Hagedoorn P. Moes J.R. Frijlink H.W. de Boer A.H. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. Eur. J. Pharm. Biopharm. 2015 97 Pt A 22 29 10.1016/j.ejpb.2015.10.003 26453913
    [Google Scholar]
  45. LeWitt P.A. Hauser R.A. Grosset D.G. Stocchi F. Saint-Hilaire M.H. Ellenbogen A. Leinonen M. Hampson N.B. DeFeo-Fraulini T. Freed M.I. Kieburtz K.D. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov. Disord. 2016 31 9 1356 1365 10.1002/mds.26611 27090868
    [Google Scholar]
  46. Urso D. Chaudhuri K.R. Qamar M.A. Jenner P. Improving the delivery of levodopa in Parkinson’s disease: A review of approved and emerging therapies. CNS Drugs 2020 34 11 1149 1163 10.1007/s40263‑020‑00769‑7 33146817
    [Google Scholar]
  47. Hay S.I. Abajobir A.A. Abate K.H. Abbafati C. Abbas K.M. Abd-Allah F. Abdulkader R.S. Abdulle A.M. Abebo T.A. Abera S.F. Aboyans V. Abu-Raddad L.J. Ackerman I.N. Adedeji I.A. Adetokunboh O. Afshin A. Aggarwal R. Agrawal S. Agrawal A. Ahmed M.B. Aichour M.T.E. Aichour A.N. Aichour I. Aiyar S. Akinyemiju T.F. Akseer N. Al Lami F.H. Alahdab F. Al-Aly Z. Alam K. Alam N. Alam T. Alasfoor D. Alene K.A. Ali R. Alizadeh-Navaei R. Alkaabi J.M. Alkerwi A. Alla F. Allebeck P. Allen C. Al-Maskari F. AlMazroa M.A.A. Al-Raddadi R. Alsharif U. Alsowaidi S. Althouse B.M. Altirkawi K.A. Alvis-Guzman N. Amare A.T. Amini E. Ammar W. Amoako Y.A. Ansha M.G. Antonio C.A.T. Anwari P. Ärnlöv J. Arora M. Artaman A. Aryal K.K. Asgedom S.W. Atey T.M. Atnafu N.T. Avila-Burgos L. Avokpaho E.F.G.A. Awasthi A. Awasthi S. Azarpazhooh M.R. Azzopardi P. Babalola T.K. Bacha U. Badawi A. Balakrishnan K. Bannick M.S. Barac A. Barker-Collo S.L. Bärnighausen T. Barquera S. Barrero L.H. Basu S. Battista R. Battle K.E. Baune B.T. Bazargan-Hejazi S. Beardsley J. Bedi N. Béjot Y. Bekele B.B. Bell M.L. Bennett D.A. Bennett J.R. Bensenor I.M. Benson J. Berhane A. Berhe D.F. Bernabé E. Betsu B.D. Beuran M. Beyene A.S. Bhansali A. Bhatt S. Bhutta Z.A. Biadgilign S. Bicer B.K. Bienhoff K. Bikbov B. Birungi C. Biryukov S. Bisanzio D. Bizuayehu H.M. Blyth F.M. Boneya D.J. Bose D. Bou-Orm I.R. Bourne R.R.A. Brainin M. Brayne C. Brazinova A. Breitborde N.J.K. Briant P.S. Britton G. Brugha T.S. Buchbinder R. Bulto L.N.B. Bumgarner B.R. Butt Z.A. Cahuana-Hurtado L. Cameron E. Campos-Nonato I.R. Carabin H. Cárdenas R. Carpenter D.O. Carrero J.J. Carter A. Carvalho F. Casey D. Castañeda-Orjuela C.A. Castle C.D. Catalá-López F. Chang J-C. Charlson F.J. Chaturvedi P. Chen H. Chibalabala M. Chibueze C.E. Chisumpa V.H. Chitheer A.A. Chowdhury R. Christopher D.J. Ciobanu L.G. Cirillo M. Colombara D. Cooper L.T. Cooper C. Cortesi P.A. Cortinovis M. Criqui M.H. Cromwell E.A. Cross M. Crump J.A. Dadi A.F. Dalal K. Damasceno A. Dandona L. Dandona R. das Neves J. Davitoiu D.V. Davletov K. de Courten B. De Leo D. De Steur H. Defo B.K. Degenhardt L. Deiparine S. Dellavalle R.P. Deribe K. Deribew A. Des Jarlais D.C. Dey S. Dharmaratne S.D. Dhillon P.K. Dicker D. Djalainia S. Do H.P. Dokova K. Doku D.T. Dorsey E.R. dos Santos K.P.B. Driscoll T.R. Dubey M. Duncan B.B. Ebel B.E. Echko M. El-Khatib Z.Z. Enayati A. Endries A.Y. Ermakov S.P. Erskine H.E. Eshetie S. Eshrati B. Esteghamati A. Estep K. Fanuel F.B.B. Farag T. Farinha C.S.S. Faro A. Farzadfar F. Fazeli M.S. Feigin V.L. Feigl A.B. Fereshtehnejad S-M. Fernandes J.C. Ferrari A.J. Feyissa T.R. Filip I. Fischer F. Fitzmaurice C. Flaxman A.D. Foigt N. Foreman K.J. Franklin R.C. Frostad J.J. Fullman N. Fürst T. Furtado J.M. Futran N.D. Gakidou E. Garcia-Basteiro A.L. Gebre T. Gebregergs G.B. Gebrehiwot T.T. Geleijnse J.M. Geleto A. Gemechu B.L. Gesesew H.A. Gething P.W. Ghajar A. Gibney K.B. Gillum R.F. Ginawi I.A.M. Gishu M.D. Giussani G. Godwin W.W. Goel K. Goenka S. Goldberg E.M. Gona P.N. Goodridge A. Gopalani S.V. Gosselin R.A. Gotay C.C. Goto A. Goulart A.C. Graetz N. Gugnani H.C. Gupta P.C. Gupta R. Gupta T. Gupta V. Gupta R. Gutiérrez R.A. Hachinski V. Hafezi-Nejad N. Hailu A.D. Hailu G.B. Hamadeh R.R. Hamidi S. Hammami M. Handal A.J. Hankey G.J. Hao Y. Harb H.L. Hareri H.A. Haro J.M. Harun K.M. Harvey J. Hassanvand M.S. Havmoeller R. Hay R.J. Hedayati M.T. Hendrie D. Henry N.J. Heredia-Pi I.B. Heydarpour P. Hoek H.W. Hoffman H.J. Horino M. Horita N. Hosgood H.D. Hostiuc S. Hotez P.J. Hoy D.G. Htet A.S. Hu G. Huang J.J. Huynh C. Iburg K.M. Igumbor E.U. Ikeda C. Irvine C.M.S. Islam S.M.S. Jacobsen K.H. Jahanmehr N. Jakovljevic M.B. James P. Jassal S.K. Javanbakht M. Jayaraman S.P. Jeemon P. Jensen P.N. Jha V. Jiang G. John D. Johnson C.O. Johnson S.C. Jonas J.B. Jürisson M. Kabir Z. Kadel R. Kahsay A. Kamal R. Kar C. Karam N.E. Karch A. Karema C.K. Karimi S.M. Karimkhani C. Kasaeian A. Kassa G.M. Kassaw N.A. Kassebaum N.J. Kastor A. Katikireddi S.V. Kaul A. Kawakami N. Keiyoro P.N. Kemmer L. Kengne A.P. Keren A. Kesavachandran C.N. Khader Y.S. Khalil I.A. Khan E.A. Khang Y-H. Khoja A.T. Khosravi A. Khubchandani J. Kiadaliri A.A. Kieling C. Kim Y.J. Kim D. Kimokoti R.W. Kinfu Y. Kisa A. Kissimova-Skarbek K.A. Kissoon N. Kivimaki M. Knudsen A.K. Kokubo Y. Kolte D. Kopec J.A. Kosen S. Kotsakis G.A. Koul P.A. Koyanagi A. Kravchenko M. Krohn K.J. Kumar G.A. Kumar P. Kyu H.H. Lager A.C.J. Lal D.K. Lalloo R. Lallukka T. Lambert N. Lan Q. Lansingh V.C. Larsson A. Leasher J.L. Lee P.H. Leigh J. Leshargie C.T. Leung J. Leung R. Levi M. Li Y. Li Y. Liang X. Liben M.L. Lim S.S. Linn S. Liu P.Y. Liu A. Liu S. Liu Y. Lodha R. Logroscino G. Looker K.J. Lopez A.D. Lorkowski S. Lotufo P.A. Lozano R. Lucas T.C.D. Lunevicius R. Lyons R.A. Macarayan E.R.K. Maddison E.R. Magdy Abd El Razek H.M.A. Magdy Abd El Razek M. Magis-Rodriguez C. Mahdavi M. Majdan M. Majdzadeh R. Majeed A. Malekzadeh R. Malhotra R. Malta D.C. Mamun A.A. Manguerra H. Manhertz T. Mantovani L.G. Mapoma C.C. March L.M. Marczak L.B. Martinez-Raga J. Martins P.H.V. Martins-Melo F.R. Martopullo I. März W. Mathur M.R. Mazidi M. McAlinden C. McGaughey M. McGrath J.J. McKee M. Mehata S. Meier T. Meles K.G. Memiah P. Memish Z.A. Mendoza W. Mengesha M.M. Mengistie M.A. Mengistu D.T. Mensah G.A. Meretoja T.J. Meretoja A. Mezgebe H.B. Micha R. Millear A. Miller T.R. Minnig S. Mirarefin M. Mirrakhimov E.M. Misganaw A. Mishra S.R. Mitchell P.B. Mohammad K.A. Mohammadi A. Mohammed M.S.K. Mohammed K.E. Mohammed S. Mohan M.B.V. Mokdad A.H. Mollenkopf S.K. Monasta L. Montañez Hernandez J.C. Montico M. Moradi-Lakeh M. Moraga P. Morawska L. Mori R. Morrison S.D. Moses M. Mountjoy-Venning C. Mruts K.B. Mueller U.O. Muller K. Murdoch M.E. Murthy G.V.S. Murthy S. Musa K.I. Nachega J.B. Nagel G. Naghavi M. Naheed A. Naidoo K.S. Nangia V. Nasher J.T. Natarajan G. Negasa D.E. Negoi R.I. Negoi I. Newton C.R. Ngunjiri J.W. Nguyen C.T. Nguyen Q.L. Nguyen T.H. Nguyen G. Nguyen M. Nichols E. Ningrum D.N.A. Nong V.M. Norheim O.F. Norrving B. Noubiap J.J.N. Nyandwi A. Obermeyer C.M. O’Donnell M.J. Ogbo F.A. Oh I-H. Okoro A. Oladimeji O. Olagunju A.T. Olagunju T.O. Olsen H.E. Olusanya B.O. Olusanya J.O. Ong K. Opio J.N. Oren E. Ortiz A. Osborne R.H. Osgood-Zimmerman A. Osman M. Ota E. Owolabi M.O. Pa M. Pacella R.E. Panda B.K. Pandian J.D. Papachristou C. Park E-K. Parry C.D. Parsaeian M. Patil S.T. Patten S.B. Patton G.C. Paudel D. Paulson K. Pearce N. Pereira D.M. Perez K.M. Perico N. Pesudovs K. Peterson C.B. Petri W.A. Petzold M. Phillips M.R. Phipps G. Pigott D.M. Pillay J.D. Pinho C. Piradov M.A. Plass D. Pletcher M.A. Popova S. Poulton R.G. Pourmalek F. Prabhakaran D. Prasad N. Purcell C. Purwar M. Qorbani M. Quintanilla B.P.A. Rabiee R.H.S. Radfar A. Rafay A. Rahimi K. Rahimi-Movaghar A. Rahimi-Movaghar V. Rahman M.H.U. Rahman M.A. Rahman M. Rai R.K. Rajsic S. Ram U. Ranabhat C.L. Rangaswamy T. Rankin Z. Rao P.V. Rao P.C. Rawaf S. Ray S.E. Reiner R.C. Reinig N. Reitsma M. Remuzzi G. Renzaho A.M.N. Resnikoff S. Rezaei S. Ribeiro A.L. Rivas J.C. Roba H.S. Robinson S.R. Rojas-Rueda D. Rokni M.B. Ronfani L. Roshandel G. Roth G.A. Rothenbacher D. Roy A. Rubagotti E. Ruhago G.M. Saadat S. Safdarian M. Safiri S. Sagar R. Sahathevan R. Sahraian M.A. Salama J. Saleh M.M. Salomon J.A. Salvi S.S. Samy A.M. Sanabria J.R. Sanchez-Niño M.D. Santomauro D. Santos J.V. Santos I.S. Santric Milicevic M.M. Sartorius B. Satpathy M. Sawhney M. Saxena S. Schelonka K. Schmidt M.I. Schneider I.J.C. Schöttker B. Schutte A.E. Schwebel D.C. Schwendicke F. Seedat S. Sepanlou S.G. Servan-Mori E.E. Shaheen A. Shaikh M.A. Shamsipour M. Sharma R. Sharma J. She J. Shi P. Shibuya K. Shields C. Shifa G.T. Shiferaw M.S. Shigematsu M. Shiri R. Shirkoohi R. Shirude S. Shishani K. Shoman H. Siabani S. Sibai A.M. Sigfusdottir I.D. Silberberg D.H. Silva D.A.S. Silva J.P. Silveira D.G.A. Singh J.A. Singh O.P. Singh N.P. Singh V. Sinha D.N. Skiadaresi E. Slepak E.L. Smith D.L. Smith M. Sobaih B.H.A. Sobngwi E. Soljak M. Sorensen R.J.D. Sousa T.C.M. Sposato L.A. Sreeramareddy C.T. Srinivasan V. Stanaway J.D. Stathopoulou V. Steel N. Stein D.J. Steiner C. Steinke S. Stokes M.A. Stovner L.J. Strub B. Subart M. Sufiyan M.B. Sunguya B.F. Sur P.J. Swaminathan S. Sykes B.L. Sylte D. Szoeke C.E.I. Tabarés-Seisdedos R. Tadakamadla S.K. Taffere G.R. Takala J.S. Tandon N. Tanne D. Tarekegn Y.L. Tavakkoli M. Taveira N. Taylor H.R. Tegegne T.K. Tehrani-Banihashemi A. Tekelab T. Terkawi A.S. Tesfaye D.J. Tesssema B. Thakur J.S. Thamsuwan O. Theadom A.M. Theis A.M. Thomas K.E. Thomas N. Thompson R. Thrift A.G. Tobe-Gai R. Tobollik M. Tonelli M. Topor-Madry R. Tortajada M. Touvier M. Traebert J. Tran B.X. Troeger C. Truelsen T. Tsoi D. Tuzcu E.M. Tymeson H. Tyrovolas S. Ukwaja K.N. Undurraga E.A. Uneke C.J. Updike R. Uthman O.A. Uzochukwu B.S.C. van Boven J.F.M. Varughese S. Vasankari T. Veerman L.J. Venkatesh S. Venketasubramanian N. Vidavalur R. Vijayakumar L. Violante F.S. Vishnu A. Vladimirov S.K. Vlassov V.V. Vollset S.E. Vos T. Wadilo F. Wakayo T. Wallin M.T. Wang Y-P. Weichenthal S. Weiderpass E. Weintraub R.G. Weiss D.J. Werdecker A. Westerman R. Whiteford H.A. Wijeratne T. Williams H.C. Wiysonge C.S. Woldeyes B.G. Wolfe C.D.A. Woodbrook R. Woolf A.D. Workicho A. Xavier D. Xu G. Yadgir S. Yaghoubi M. Yakob B. Yan L.L. Yano Y. Ye P. Yihdego M.G. Yimam H.H. Yip P. Yonemoto N. Yoon S-J. Yotebieng M. Younis M.Z. Yu C. Zaidi Z. Zaki M.E.S. Zegeye E.A. Zenebe Z.M. Zhang X. Zheng Y. Zhou M. Zipkin B. Zodpey S. Zoeckler L. Zuhlke L.J. Murray C.J.L. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017 390 10100 1260 1344 10.1016/S0140‑6736(17)32130‑X 28919118
    [Google Scholar]
  48. Muller T. Kuoppamaki M. Vahteristio M. Aho V. Ellmen J. Trenkwalder C. Novel levodopa product ODM-101 vs levodopa/carbidopa/entacapone in Parkinson’s disease with response fluctuations. Mov. Disord. 2013 28 409
    [Google Scholar]
  49. LeWitt P.A. Giladi N. Navon N. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson’s disease. Parkinsonism Relat. Disord. 2019 65 131 138 10.1016/j.parkreldis.2019.05.032 31176632
    [Google Scholar]
  50. Verhagen Metman L. Stover N. Chen C. Cowles V.E. Sweeney M. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson’s disease. Mov. Disord. 2015 30 9 1222 1228 10.1002/mds.26219 25847690
    [Google Scholar]
  51. Chordiya M. Gangurde H. Borkar V. Technologies, optimization and analytical parameters in gastroretentive drug delivery systems. Curr. Sci. 2017 112 5 946 953 10.18520/cs/v112/i05/946‑953
    [Google Scholar]
  52. Tambasco N. Romoli M. Calabresi P. Levodopa in Parkinson’s disease: Current status and future developments. Curr. Neuropharmacol. 2018 16 8 1239 1252 10.2174/1570159X15666170510143821 28494719
    [Google Scholar]
  53. Pagano G. Yousaf T. Politis M. PET molecular imaging research of levodopa-induced dyskinesias in Parkinson’s disease. Curr. Neurol. Neurosci. Rep. 2017 17 11 90 10.1007/s11910‑017‑0794‑2 28975571
    [Google Scholar]
  54. Jimenez-Shahed J. A review of current and novel levodopa formulations for the treatment of Parkinson’s disease. Ther. Deliv. 2016 7 3 179 191 10.4155/tde.15.96 26893250
    [Google Scholar]
  55. Castro-Caldas A. Delwaide P. Jost W. Merello M. Williams A. Lamberti P. Aguilar M. Del Signore S. Cesaro P. The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov. Disord. 2006 21 4 500 509 10.1002/mds.20750 16267842
    [Google Scholar]
  56. Kalecký K. Bottiglieri T. Targeted metabolomic analysis in Parkinson’s disease brain frontal cortex and putamen with relation to cognitive impairment. NPJ Parkinsons Dis. 2023 9 1 84 10.1038/s41531‑023‑00531‑y 37270646
    [Google Scholar]
  57. LeWitt P.A. Huff F.J. Hauser R.A. Chen D. Lissin D. Zomorodi K. Cundy K.C. Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov. Disord. 2014 29 1 75 82 10.1002/mds.25742 24339234
    [Google Scholar]
  58. LeWitt P.A. Ellenbogen A. Chen D. Lal R. McGuire K. Zomorodi K. Luo W. Huff F.J. Actively transported levodopa prodrug XP21279: A study in patients with Parkinson disease who experience motor fluctuations. Clin. Neuropharmacol. 2012 35 3 103 110 10.1097/WNF.0b013e31824e4d7d 22406623
    [Google Scholar]
/content/journals/cdth/10.2174/0115748855311148240923100039
Loading

  • Article Type:     Review Article
Keywords: treatment strategies ; neurodegeneration ; carbidopa ; Parkinson’s disease ; drug targeting ; levodopa

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test